HemaSphere Journal
The official open access journal of EHA - we publish basic, translational, & clinical heme research. 2024 stats: #ImpactFactor = 14.6 (ranked #5).
#hematology #ScientificPublishing #BloodSky #HemeSky
👓 hemaspherejournal.com
- This recently published paper shows that patients with #MPNs experience notable impairments in daily functioning, especially fatigue. The authors highlight that clinicians often underestimate symptom burden, reinforcing the need for routine patient‑reported outcomes 👉bit.ly/4q2Zwcb
- The authors report that non‑TCR TLX1‑positive #T‑ALL arises mainly from chromosomal changes that reposition ANKRD1 and PCGF5 enhancers near TLX1. This paper links this mechanism to distinct disease features and reduced survival. Dig deeper👉bit.ly/4sqiyLh
- This paper shows that venetoclax‑rituximab retreatment can achieve renewed clinical responses in patients with relapsed CLL/SLL who previously stopped therapy after a deep response. Authors highlight its potential to extend long‑term disease control. In depth 👉 bit.ly/44Sa9Gu
- In this paper, authors report that elevated baseline sVCAM‑1 and sIL‑2R identify patients at higher risk for prolonged neutropenia, severe infections, and inferior survival after CAR‑T therapy. Authors suggest these markers can support more individualized management.👉bit.ly/3Kzsv88
- According to authors, long‑term benefit from anti‑BCMA CAR‑T in RRMM is driven more by a patient’s immune profile and tumor burden than by CAR‑T‑cell features. The authors propose a risk score to help identify patients most likely to achieve durable responses 👉bit.ly/499jE6I
- In this Review authors discuss that atypical #CML has sig. dx challenges, diverse mutations & no standard of care, stressing need for better prognostic tools & confirm that allogeneic transplant remains the sole curative therapy, w/ targeted agents under investigation👉bit.ly/3XL9xOM
- Daratumumab‑based treatment leads to rapid, deep responses in #AL amyloidosis. The authors highlight that achieving a very good partial response within one month strongly predicts longer EFS and OS. Read more about the process bit.ly/4qCIL7t
- This Editorial stresses the need for harmonized research, consistent clinical standards, better training, and stronger global coordination in #hemoglobinopathies. The authors propose practical steps to address these long‑standing challenges. Read how 👉 bit.ly/4pPzqZK
- This paper indicates that #PMBL relapse after #CAR‑T requires quick, individualized decisions. The authors highlight checkpoint inhibitor–based regimens as a preferred option and call for coordinated input from multiple specialists. Read more about the findings here bit.ly/48FqYVZ
- Authors demonstrate that impaired CAR T cell function in #CLL may stem from greater exhaustion and microenvironmental suppression, highlighting that IL 10 or CXCR4 inhibition can significantly improve cytotoxicity in a 3D co culture model. Read more about this here bit.ly/48FY0Fn
- Findings in this paper report that the 𝘝𝘏𝘓ᴿ²⁰⁰ᵂ mutation increases erythropoietin and transferrin, both tied to suppressed hepcidin. This suggest a model where iron balance and HIF‑driven erythropoiesis act together to regulate hepcidin. Read more in depth 👉 bit.ly/48ASZxW
- 🚨In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research bit.ly/4nIhH68
- This recent HemaTopics from Scientific Editor S Hibbs underlines that discussions of “cure” in #SCD must consider medical, emotional, and social dimensions. Authors encourage clinicians to communicate with nuance, clarity, and awareness of individual experience. 👉 f.mtr.cool/spprnmlkcs
- Authors in this recently published paper show that MMS22L plays a critical role in red cell formation. Its reduced function, together with CDAN1 defects, impairs erythroid development and offers fresh insight into congenital dyserythropoietic anemia. 📰bit.ly/3YthgS9
- 🩺 Enhance your clinical practice with HemaSphere Journal! Access harmonized #guidelines and the latest research to improve patient care. Find them in our virtual bookshelf 📖 bit.ly/4kETU4u #Hematology #ClinicalPractice #PatientCare
- In this retrospective real-life study, authors evaluate the prognostic significance of early-POD specifically among relapsed/refractory (r/r) #MCL patients ≥ 65 years old. Read more here 👉f.mtr.cool/ghksgnnktd
- This paper shows that DNMT3A-mutant blood stem cells, present but undetectable in young donors, can expand into clonal hematopoiesis decades after transplantation. The authors highlight that environmental pressures, not just new mutations, drive this process. Read here 👉bit.ly/3XLdF1m
- This HemaTopics series from Sci Ed L Merz explains why updating neutrophil count grading in CTCAEv6 is an important step twd inclusive & clinically meaningful safety reporting. New thresholds reflect infection risk & modern therapies 📰 1️⃣f.mtr.cool/pamfqpxovh 2️⃣f.mtr.cool/jtwtvhxcyh
- This paper shows that anti-CD19 CAR NK cells, when combined with targeted drugs, can improve outcomes for high-risk BCP-ALL. The authors highlight the potential of this approach for long-term remission and recommend further clinical evaluation. Read it here 👉bit.ly/3JfNMmz
- The treatment landscape of hematologic malignancies is changing with a shift away from chemo- and radiotherapy towards targeted approaches and immunotherapies. The European Hematology Association (#EHA) has championed several activities, summarized in this Perspective. 👉bit.ly/4haRASx
- Authors of this paper show that 8 weeks of vemurafenib plus rituximab leads to high complete remission and minimal toxicity in relapsed/refractory hairy-cell leukemia, confirming strong results in real-world clinical practice Read more about this study here 👉bit.ly/4nPh3Tf
- 🔬Podcast Episode! Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL. 🎧 Listen now on all major platforms & read the full open-access article bit.ly/4oeJo6w #Hematology
- 2025 has been a successful year for HemaSphere Journal! 1000+ manuscript submissions increasing impact in the field insightful graphical abstracts another podcast season ...and of course, excellent research! We extend a warm thank you to all authors, reviewers & readers ❤️
- The 2024 International Symposium on Hodgkin Lymphoma workshop highlighted critical challenges and opportunities in the harmonization of clinical trial reporting for HL. This Perspective highlights some of the takeaways and recommendations, read it on our website 👉bit.ly/46NxD1a
- In this paper published in the November issue, specific HLA genotypes and diversity influence chronic myeloid leukemia risk and treatment outcomes. Authors suggest HLA typing may help guide therapy choices and predict remission or relapse. Read more about it here👉bit.ly/3LG7RDt
- Read the latest HemaTopics from Scientific Editor Stephen Hibbs: As the ability to detect deviations from the norm grows ever greater, we must remember that labelling and monitoring such deviations is only sometimes helpful. 👉bit.ly/4o6l468
- 🚨New! In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research bit.ly/4nIhH68
- Authors aimed to evaluate the impact of prior CD19-directed therapy on subsequent CD19-based treatment, focusing on the impact of prior CD19 CAR T on tafa/len efficacy, comparing CAR T-exposed versus CAR T-naïve patients receiving tafa/len. Read more here👉bit.ly/3LKVxlr
- The HemaSphere office at EHA will be closed Dec 24-Jan 4, while we take time to rest + gear up for 2026. Our #openaccess content is always available www.hemaspherejournal.com Should you need immediate help, feel free to contact our colleagues at Wiley: hemasphere at wiley dot com
- This Guidelines paper recommends prioritizing CAR T-cell therapy over bispecific antibodies or ADCs for eligible relapsed/refractory myeloma patients, as prior use of certain agents may reduce CAR T-cell effectiveness. 👉bit.ly/4rn5d5K
- In this paper authors present a new RNA-based model that improves risk assessment for infant AML. The authors show it outperforms previous methods and can guide more precise treatment decisions, especially regarding stem cell transplantation. Read more 👉bit.ly/43SOq0i
- HemaTopics are HemaSphere pubs focusing on 🔥 heme topics. The latest by Sci Ed C de Bock, discusses 2 studies showing that combining menin inhibitors w/ KAT6/7 inhibitors may help overcome resistance in high-risk #AML, offering a promising approach for pts bit.ly/49u8BW5
- New research uncovers how anthracyclines epigenetically upregulate ALDH1 isoforms, as adaptive response in AML and that dual ALDH1A1/1A2 inhibition has anti-leukemic activity Read it here 👉bit.ly/47zh9IL
- 📚 Never stop learning with HemaSphere Journal! Access high-quality hematology publications, always #OpenAccess. Our current issue in progress can always be found here 👉bit.ly/3GIlBvj #OpenAccess #MedicalEducation #CareerDevelopment
- This paper shows that while corticosteroids are safe for managing CAR-T cell therapy side effects in large B-cell lymphoma, higher doses may increase infection risk and late blood toxicity. Judicious use is advised for optimal patient outcomes Read more about it 👉bit.ly/4rnh6J1
- Podcast Playlists 📺 We've compiled our recommended podcasts into an easy-to-browse playlist format. Explore our current podcast selections organized by series. Even easier, start with the Top 5 Trending! You've read the paper, now hear the story. Top 5 monthly: bit.ly/453lYcF
- Comprehensive molecular sequencing at the institutional level can identify actionable biomarkers in most pediatric and #AYA leukemia cases, supporting more precise risk assessment and targeted therapies to improve patient outcomes. 👉bit.ly/4op13rv
- This consensus Guidelines paper assesses whether next-generation sequencing (#NGS) could complement or even replace fluorescence in situ hybridization (FISH) at diagnosis. 👉bit.ly/4n7iPPx
- Our December issue is now open! The first papers have been published, have you seen them? bit.ly/44MwULI
- Authors show that patients with IDH-mutated myeloid neoplasms and immune-mediated inflammatory disorders respond well to targeted IDH inhibitors, improving both blood and inflammatory symptoms. This approach may offer new treatment options. Read here👉bit.ly/3K08fMK #MN
- Relapse after CD19-CAR T-cell therapy in B-cell #ALL is common, with early B-cell recovery signaling higher risk. An international group has now set consensus criteria for BCR to standardize monitoring and improve post-therapy care in this recent Guidelines paper. 👉bit.ly/3WO8gpR
- Greetings from #ASH25. We already tested the nap pods for you 😅 Outcomes were very encouraging so we will try again today to increase the sample size of this new unofficial study. Have a great opening ASH day, everybody! #WhoNeedsJetLag #ASHScavengerHunt #HemaSphereHumans
- 🚨New! In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research bit.ly/4nIhH68
- #HemaSphere is heading to #ASH25 Are you interested to learn more? Looking to discuss your manuscript? Curious about who we are? Reach out - we can set a meeting time. Jessica will also be available at the #EHA booth (1482) at various times. See you in Orlando!
- This newly published paper presents a rapid, accurate diagnostic method for hemoglobinopathies. The authors combine high-throughput proteomics and machine learning, offering a scalable alternative to traditional tests for hereditary anemias. Read more 👉 bit.ly/3XuVSep
- 🩸 Fresh in HemaSphere Vol. 9(11): . Explore cutting-edge hematology research in our recent November issue! 👉bit.ly/44KWY9U
- APCs will change as of January 1, 2026 submissions. This new rate is for the '26 & '27 calendar years. HemaSphere’s 2026-2027 APCs remain competitively priced at: • Tier 1 - Articles, Review Articles, Guidelines: €2500 • Tier 2 - Perspectives, Letters: €1500 • Tier 3 - Editorials, Comments: €0
- 🚨Here's a sneak peak of the newest episode, which is based on a must-read Perspective "Can health inequalities in sickle cell disease be addressed through novel therapies?" Host Charles de Bock discusses #SCD with co-authors: experts & patient perspective. 📺
- This recently published paper highlights that while CAR T-cell therapy processes are broadly aligned, differences in implementation across manufacturers create inefficiencies and duplicate oversight, increasing hospital workload and diverting focus from patient care 👉bit.ly/4htzxXT
